This editorial paper refers to papers in the supplement, Hyperprolactinaemia in schizophrenia and bipolar disorder: Clinical Implications ( 2008) Supplement to the Journal of Psychopharmacology volume 22. Additional references that support this editorial are given below.
2.
Beumont PJ, Gelder MG, Friesen HG, Harris G., Mackinnon P., Mandelbrote BM, Wiles JM (1974) The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Brit J Psychiatry124: 413-419
3.
Barnett AH, Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., Hill J., Millar H., Peveler R., Rees A., Singh V., Taylor D., Vora J., Jones P. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: 10.1177/0269881106075509
4.
Brown S., Inskip H., Barraclough B. (2000) Causes of the excess mortality of schizophrenia . The Brit J Psychiatry177: 212-217
5.
Bushe C., Shaw M. ( 2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol21: 768-773
6.
Dalton SO, Mellemkjaer L., Thomassen L., Mortensen PB, Johansen C. (2005) Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res75: 315-324
7.
Disability Rights Commission Report (2006). Equal treatment closing the gap.
8.
Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., Eerdekens M. (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res . 90: 147-161
9.
Klibanski A., Neer R.Beitins, Ridgeway C, Zervas N, McArthur (1980) Decreased bone density in hyperprolactinaemia women . New Engl J Med303: 1511-1514
10.
Kockott G., Pfeiffer W. (1996) Sexual disorders in nonacute psychiatric outpatients . Comp Psychiatry37: 56-61
11.
Meltzer HY, Sachar EJ, Frantz AG (1974) Serum prolactin levels in newly admitted psychiatric patients. Neuropsychopharmacology of monoamines and their regulatory enzymes . Raven Press, New York
12.
Osborn DJP, Levy G., Nazareth I., Peterson I., Islam A., King MB ( 2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database Arch Gen Psychiatry64: 242-249
13.
Riddle O., Bates RW, Dykshorn SW (1933) The preparation, identification and assay of prolactin - a hormone of the anterior pituitary. Am J Physiol105: 191-216
14.
Smith S., O'Keane V., Murray R. (2002) Sexual dysfunction in patients taking conventional antipsychotic medication. Brit J Psychiatry181: 49-55
Szarfman A., Tonning JM, Levine JG, Doraiswamy PM (2006) Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy26: 748-758
17.
Tworoger SS, Eliassen AH, Rosner B., Sluss P., Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res64: 6814-6819
18.
Tworoger SS, Sluss P., Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. Cancer Res66: 2476-2482
19.
Tworoger S., Eliassen H., Sluss P., Hankinson S. (2007). A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol25: 1-7
20.
Wang PS, Walker AM, Tsuang MT (2002). Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry59: 1147- 1154
21.
Weiden P., Mackell JA, McDonell D. (2002) Sexual dysfunction and adherence to antipsychotic therapy in schizophrenia. Eur Neuropsychopharmacol12(Suppl 3): 316-317
